Product Description
Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31249721/)
Mechanisms of Action: MAP3K1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Melanoma
Known Adverse Events: Lymphedema | Diarrhea | Edema
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: BeiGene
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Netherlands, New Zealand, Norway, Puerto Rico, Russia, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Melanoma|Oncology Unspecified|Ovarian Cancer|Peritoneal Cancer|Thyroid Cancer
Phase 2: Acute Lymphoid Leukemia|Adamantinoma|Cholangiocarcinoma|Colorectal Cancer|Craniopharyngioma|Glioma|Lung Cancer|Lymphoma, Non-Hodgkin|Neurofibroma, Plexiform|Neurofibromatoses|Neurofibromatosis 1|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer
Phase 1: Anaplastic Thyroid Carcinoma|Central Nervous System Cancer|Multiple Myeloma|Sarcoma|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HEM-iSMART D | P2 |
Recruiting |
Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2029-04-01 |
|
| CheckMate 9N9: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9N9 | P2 |
Active, not recruiting |
Colorectal Cancer |
2029-03-12 |
|
| ERAS-254-02 | P3 |
Unknown Status |
Melanoma |
2028-07-30 |
|
| SEACRAFT-2 | P3 |
Recruiting |
Melanoma |
2028-04-01 |